|
OBN Member Arecor and JDRF sign an agreement to develop a co-formulation
insulin for the treatment of diabetes
|
On Friday 25 October Arecor announced that it had signed a Research, Development and Commercialisation agreement with JDRF, the leading global organisation funding type 1 diabetes (T1D) research.
Under this collaboration, Arecor and JDRF will contribute matching funds to develop a stable, liquid co-formulation of pramlintide and insulin (AT271) for people living with diabetes who require prandial insulin treatment. It has been demonstrated that the combined injection of pramlintide and insulin at meal-times results in significantly improved treatment outcomes, such as enhanced post prandial glucose control, improved HbA1c, weight loss and concomitant reduction in insulin doses. Currently pramlintide is underutilised despite these significant benefits as it requires the patient to administer daily injections in addition to their insulin injections. Therefore, combination treatment, AT271, would reduce the burden of use by providing a single injection treatment option for pramlintide and prandial insulin.
Arecor will use its proprietary formulation technology platform, Arestat™, to develop a new, co-formulation of pramlintide and insulin. This will be in accordance with a Development Programme, monitored by a Joint Steering Committee, which will include non-clinical studies to develop a new product. This contract will be managed under the JDRF standard terms for industry partnerships.
Sarah Howell, Chief Executive Officer at Arecor, said: "We are delighted to be collaborating with JDRF. The development of a co-formulation of pramlintide-insulin has the promise to significantly improve the quality of life for people living with diabetes by enabling more effective management of this condition. This collaboration reflects the investment we are making in our proprietary portfolio of diabetes products and we appreciate the support of such a prestigious organisation as JDRF.
JDRF scientist Jonathan Rosen, PhD, said: "Arecor's expertise in enhancing current therapies supports our drive to target life-changing breakthroughs to help people better manage type 1 diabetes and ultimately find cures for the disease. An insulin-pramlintide co-formulation will allow people with type 1 diabetes to achieve better glucose control, improving quality of life and in all likelihood ultimately reducing long-term complications."
|
 |
|
We are delighted to announce the confirmed line up of Health Tech and Medical Device companies showcasing at our next
BioTuesday
event in Bristol on
Tuesday 19 November - please see below.
As well as the showcase element, the evening will also feature several keynotes from experts in this space, who will share updates on areas such as investment, regulatory, market access and IP.
We have complimentary tickets available for OBN Members and members of the scientific community, with other tickets charged at a nominal fee, so if you are keen to attend, please click on the above link to book.
|
|
|
If you are seeking seed stage funding for your start-up life sciences company, and not yet confirmed your pitching slot at
BioSeed 2020
on
Monday 20 January
in Canary Wharf, London - there's still time - enquire about booking
We have had a great response so far from companies registering to showcase. To see the full list please click
here
.
The BII offers entrepreneurially-minded researchers or anyone with a research-based idea help to bring interdisciplinary ideas to life and research to market.
They offer state-of-the-art facilities and various funding opportunities, as well as partnerships and programs with technical, scientific and commercial experts.
BioSeed
provides an affordable platform for up to 60 innovative early-stage life sciences companies to deliver their 5-minute pitch to 100 specialist investors, followed by an afternoon of extensive networking and one-to-one partnering meetings.
Not booked yet? There's still time...
|
|
|
We are all looking forward to our 11th OBN Awards event next week being held at The Examinations Schools in Central Oxford. This will be a glittering evening focused on celebrating some of the most inspirational companies and individuals from across the life sciences industry.
The number of entries has increased once again this year, with the quality of entries and levels of innovation consistently impressive across all categories, so it promises to be a fantastic evening.
|
|
Getting to know the OBN Team
|
This month Jonathan Rohll has kindly shared his story..
"I joined OBN in early 2012 on an 8-week project which OBN were doing for the Welsh Governm
ent - and have been here since. At that time I was juggling a number of things: being an osteopath, lecturing pathophysiology and embryology at Brookes on the osteopathy course and being the main child care function for my family. Prior to this I worked for Oxford BioMedica on developing their lentiviral vector system - this was from 1997 to 2003.
Doing the osteopathy training and lecturing massively broadened my knowledge of medicine and health and I believe makes me more effective in my job at OBN - at any rate it is certainly more enjoyable. I have a real passion for medical science and get a real kick from learning about what is going on in the biotech/medtech fields especially with respect to the OBN Member companies. I particularly like trying to help them make progress.
Outside work I am involved in lots of different stuff: keeping fit through cycling/running, gardening, acting, woodwork, reading history etc., etc - and I have also done some BD work for a consultant friend who has developed an improved device for tear drainage where that is defective. I do like food (as any one at OBN will confirm) and am always keen to hear about good restaurants in the local area. I have two kids who are almost off the payroll - one works in London and the other is at UPenn. My wife Catherine was a Partner in the Manches Penningtons Life Sciences team but now works for an engineering firm in Banbury - Norbar Torque Tools."
OBN has a lot of contacts and so if you think that Jonathan could help you/your organisation then please contact him at
[email protected] or call him on +44 (0) 1235 420 877.
|
|
'How the Drug Discovery Industry Works'
Tuesday 19 November
12:00 - 17:00, Oxford
|
South West Health Tech & Medical
Device Showcase
Tuesday 19 November
17:30 - 21:00, Bristol
|
Science Social
Thursday 26 November
18:00 - 20:00
Oxford
|
If you are an OBN Member and not a One Nucleus Member you are entitled to a 10% discount to attend Genesis 2019 - just email
Rebecca Wilkes at OBN for the code.
|
Follow us on
|
If you have any News, Jobs or Events you would like to share with OBN Members and Contacts, email
Rebecca with the details.
|
|
|
|
|
Provide cell biology services and solutions to organisations that use mammalian cells in their drug discovery workflows.
An innovative microbial genome sequencing and strain repository service.
Is a world leader in the discovery, development and commercialisation of recombinant and native enzymes for genomic research.
International law firm with offices across the UK, Europe, the Middle East, Africa and Asia.
|
Contact
Lee Pratley to find out how you can make huge savings on Lab and office supplies, business travel, utility bills and our new Purchasing Platform!
|
and login
to view the details of
discounts
you can receive as an OBN Member to attend a wide range of events, or contact
|
|
US market entry advice - UK visit by Virginia Beach Bio 5-6 December 2019
|
If you are loo
king at entering or expanding in the US healthcare market, you might like to meet a small team from Virginia Beach Bio. They will be in the London, Oxford and Cambridge areas on 5th and 6th December.
Virginia Beach is one of the fastest growing biotech hubs in the USA; their bio initiative helps businesses from overseas to set up facilities, and work with local companies and advisers.
|
|
|
|
Is it time you asked for that pay rise? What effect is Brexit going to have on your job prospects? There's a lot of uncertainty out there in the jobs market.
At SRG our mission is to cut through it, giving you the very best insight on salary and market trends in STEM.
To do that, we need your help. We've teamed up with New Scientist Jobs to create the most comprehensive industry and salary report, and we'd like your input. More than 3,500 scientists, engineers, academics and specialists contributed to last year's survey, which revealed among other things a 9.9 % increase in the average UK scientific salary.
The survey shouldn't take more than 10 minutes to complete. Take part, and you'll be entered into a prize draw for a chance to win one of five £100 Amazon vouchers, or Euro equivalent. Click
The report will be available on early next year - allowing you to plan your career better.
Thanks for your help and support!
|
|
If you haven't already joined OBN please take a look at all the benefits of becoming an OBN Member and...
|
|
|
|
|
